KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Castle Biosciences (CSTL) over the last 8 years, with Q2 2025 value amounting to $2.2 million.

  • Castle Biosciences' Gains from Investment Securities rose 25317.07% to $2.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 7296.03%. This contributed to the annual value of $8.8 million for FY2024, which is 7066.61% up from last year.
  • According to the latest figures from Q2 2025, Castle Biosciences' Gains from Investment Securities is $2.2 million, which was up 25317.07% from $2.5 million recorded in Q1 2025.
  • Castle Biosciences' 5-year Gains from Investment Securities high stood at $6.4 million for Q4 2024, and its period low was -$20.4 million during Q2 2022.
  • In the last 5 years, Castle Biosciences' Gains from Investment Securities had a median value of $954500.0 in 2024 and averaged $137357.1.
  • Within the past 5 years, the most significant YoY rise in Castle Biosciences' Gains from Investment Securities was 786363.64% (2022), while the steepest drop was 11217.04% (2022).
  • Quarter analysis of 5 years shows Castle Biosciences' Gains from Investment Securities stood at $2.5 million in 2021, then crashed by 112.17% to -$300000.0 in 2022, then soared by 1438.33% to $4.0 million in 2023, then soared by 58.88% to $6.4 million in 2024, then plummeted by 65.95% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q2 2025, $2.5 million for Q1 2025, and $6.4 million during Q4 2024.